Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 26, 2025MedScienOpen Access

Can Targeted Drugs Developed from the Study of Human Endogenous Retrovirus K Replace Traditional Chemotherapy in terms of Colorectal Tumors?

View Full Paper
Ask AI
Bookmark
Share

Authors

JYJiahe Yu

Discussion

Loading...

Member takes

Overview

This dissertation reviews HERV-K's role in colorectal cancer, suggesting targeted therapies may reduce chemotherapy's side effects.

Key Points

  • Targeted therapies based on HERV-K show promise in reducing side effects compared to chemotherapy, but are still in early development.
  • HERV-K's link to carcinogenesis and its expression in tumors highlight its potential as a novel target for colorectal cancer treatment.
  • Emerging strategies like CRISPR-based gene editing and immune activation require further investigation and validation in clinical settings.
  • Despite promising findings, HERV-K therapies face economic hurdles and are not yet a replacement for traditional chemotherapy.

Cite This Study

Jiahe Yu (2025) studied this question.

synapsesocial.com/papers/68af61fdad7bf08b1eae28d1https://doi.org/10.61173/27xe3f16
View Full Paper
Ask AI
Bookmark
Share